Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design and delivery, has announced an exclusive Development and Commercial License Agreement for the company’s AppiForm™ Modular Release System with Capsugel, the world's leading provider of dosage form solutions to the pharmaceutical and related healthcare industries. The agreement provides for Capsugel to utilize the AppiForm Modular Release System for customizable drug delivery profiles.

Under the terms of the agreement, Capsugel will have exclusive rights to the AppiForm Modular Release System technology that enables custom-matching of desired release kinetics. The AppiForm platform formulations can be used to develop oral dosage forms with unique release profiles that include periods of delayed action, controlled decreasing rate or even increasing rate of release as well as zero order delivery. The unique design of the AppiForm system allows for release of several drugs or beneficial agents in sequential mode at constant or decreasing rates.

Appian Labs President Brian Windsor said, “We are extremely pleased to partner with Capsugel in exclusive development. The types of release profiles afforded by the AppiForm system are increasingly in demand globally. As both a leader and innovator in pharmaceutical products and services, Capsugel is a perfect fit for developing and launching the AppiForm technology.”

Dr. Keith Hutchison, Vice President of Research and Development for Capsugel, remarked, “This agreement with Appian Labs supports our strategy to offer a wide range of oral dosage form solutions to our healthcare customers around the world. The drug delivery performance of the AppiForm technology is impressive. It will allow our customers to achieve customized release profiles for their API’s, and at the same time to bring new products to market by taking advantage of Capsugel’s manufacturing know-how.”